196 related articles for article (PubMed ID: 10386642)
1. Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience.
Machtay M; Seiferheld W; Komaki R; Cox JD; Sause WT; Byhardt RW
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):847-53. PubMed ID: 10386642
[TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy.
Oh D; Ahn YC; Park HC; Lim DH; Noh JM; Cho WK; Pyo H
Oncotarget; 2017 May; 8(22):35700-35706. PubMed ID: 28415687
[TBL] [Abstract][Full Text] [Related]
3. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
4. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
5. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.
Machtay M; Hsu C; Komaki R; Sause WT; Swann RS; Langer CJ; Byhardt RW; Curran WJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):667-71. PubMed ID: 15927409
[TBL] [Abstract][Full Text] [Related]
6. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
[TBL] [Abstract][Full Text] [Related]
7. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
Firat S; Byhardt RW; Gore E
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
[TBL] [Abstract][Full Text] [Related]
8. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center.
Komaki R; Roth JA; Walsh GL; Putnam JB; Vaporciyan A; Lee JS; Fossella FV; Chasen M; Delclos ME; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):347-54. PubMed ID: 10974447
[TBL] [Abstract][Full Text] [Related]
9. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
Cicenas S; Zaliene A; Atkocius V
Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
[TBL] [Abstract][Full Text] [Related]
10. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy.
Ball D; Smith J; Wirth A; Mac Manus M
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1007-13. PubMed ID: 12419426
[TBL] [Abstract][Full Text] [Related]
11. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
12. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
[TBL] [Abstract][Full Text] [Related]
13. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.
Werner-Wasik M; Scott C; Cox JD; Sause WT; Byhardt RW; Asbell S; Russell A; Komaki R; Lee JS
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1475-82. PubMed ID: 11121651
[TBL] [Abstract][Full Text] [Related]
14. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.
Movsas B; Scott C; Sause W; Byhardt R; Komaki R; Cox J; Johnson D; Lawton C; Dar AR; Wasserman T; Roach M; Lee JS; Andras E
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1143-9. PubMed ID: 10613306
[TBL] [Abstract][Full Text] [Related]
15. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer.
Liao Z; Komaki R; Stevens C; Kelly J; Fossella F; Lee JS; Allen P; Cox JD
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):558-65. PubMed ID: 12062597
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
17. Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Noh JM; Kim JM; Ahn YC; Pyo H; Kim B; Oh D; Ju SG; Kim JS; Shin JS; Hong CS; Park H; Lee E
Cancer Res Treat; 2016 Jan; 48(1):106-14. PubMed ID: 25687865
[TBL] [Abstract][Full Text] [Related]
18. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
[TBL] [Abstract][Full Text] [Related]
19. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11.
Curran WJ; Cox JD; Azarnia N; Byhardt RW; Shin KH; Emani B; Phillips TL; Selim H; Herskovic A; Mohiuddin M
Cancer; 1991 Aug; 68(3):509-16. PubMed ID: 1648432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
